Ameriflex Group Inc. Has $1.16 Million Position in Johnson & Johnson $JNJ

Key Points

• Ameriflex Group Inc. increased its stake in Johnson & Johnson by 93.5% in the first quarter, now owning 6,997 shares valued at approximately $1.16 million.
• Johnson & Johnson reported a quarterly EPS of $2.77, exceeding expectations, and projected FY 2025 EPS guidance between 10.800 and 10.900.
• The company announced a quarterly dividend of $1.30, with a yield of 2.9% and a payout ratio of 55.61%.

Ameriflex Group Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 93.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,997 shares of the company's stock after acquiring an additional 3,381 shares during the period. Ameriflex Group Inc.'s holdings in Johnson & Johnson were worth $1,160,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of JNJ. ICW Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 0.9% during the first quarter. ICW Investment Advisors LLC now owns 16,715 shares of the company's stock worth $2,772,000 after purchasing an additional 147 shares in the last quarter. Graham Capital Management L.P. grew its stake in Johnson & Johnson by 2.9% during the 1st quarter. Graham Capital Management L.P. now owns 114,555 shares of the company's stock worth $18,998,000 after buying an additional 3,230 shares during the last quarter. Betterment LLC acquired a new position in Johnson & Johnson during the first quarter worth approximately $265,000. Retirement Planning Co of New England Inc. boosted its holdings in shares of Johnson & Johnson by 13.1% in the first quarter. Retirement Planning Co of New England Inc. now owns 5,945 shares of the company's stock valued at $986,000 after acquiring an additional 690 shares during the period. Finally, Cura Wealth Advisors LLC grew its position in shares of Johnson & Johnson by 11.9% during the first quarter. Cura Wealth Advisors LLC now owns 2,388 shares of the company's stock worth $396,000 after acquiring an additional 253 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.2%

Shares of JNJ traded down $0.35 on Wednesday, hitting $177.71. 6,832,001 shares of the stock traded hands, compared to its average volume of 7,666,583. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $427.98 billion, a P/E ratio of 17.72, a P/E/G ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The stock's 50 day moving average is $167.02 and its two-hundred day moving average is $160.33.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the business earned $2.82 earnings per share. The business's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. Bank of America upped their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Barclays increased their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Citigroup boosted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research note on Thursday, August 21st. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.